Market Snapshot – Replimune (REPL)
Replimune (REPL) closed the day at $11.99, reflecting a 2.63 % uptick during the 24‑hour window that ended at 10:22 PM Central Europe on Thursday, 22 November 2026. The stock’s trading volume over the past day totaled $25.8 million, a modest figure compared with its $1.1 billion market capitalization and 94.6 million shares outstanding.
A technical overview shows the 200‑day simple moving average anchored at $9.08, underscoring that the current price sits comfortably above this long‑term mean. In the past year, REPL’s most recent high of $16.33 was logged on 2 September 2026, while the 52‑week low of $1.50 fell on 13 April 2026, indicating a broad yet volatile trading range.
Peer Performance (Last 24 Hours)
| Symbol | 24‑hr % | Current Price | Market Cap | P/E | Key Outlook |
|---|---|---|---|---|---|
| TPB | +0.28 % | $66.87 | $1.3 bn | 28.3 | Stable growth, modest margin expansion expected |
| SG | –4.78 % | $10.22 | $1.3 bn | 53.37 | Q3 2026 earnings due 5 Nov; analysts predict a slight revenue dip but continued profitability improvement |
| TRUP | –0.90 % | $29.91 | $1.3 bn | 53.45 | Q3 2026 results to be released; guidance points to gradual EPS decline but overall growth trajectory maintained |
| SLVM | –1.79 % | $32.44 | $1.3 bn | 19 | Q3 2026 earnings announced 6 Nov; expectations of modest EPS contraction but FY earnings per share improving |
| AMSC | +3.66 % | $25.01 | $1.3 bn | 8.64 | Strong earnings beat; valuation remains attractive for infrastructure-focused investors |
Strategic Context for Replimune
Replimune Group Inc. operates as a clinical‑stage biopharmaceutical enterprise headquartered in Woburn, Massachusetts. Its portfolio centers on oncolytic immunotherapies—engineered viruses that selectively infect and destroy cancer cells while stimulating systemic anti‑tumor immunity. The company’s pipeline targets a range of solid tumours, and it maintains a robust research and development cadence aimed at advancing candidates through early‑phase clinical trials.
Since its July 20, 2018 IPO, REPL has leveraged Nasdaq’s platform to secure capital for research, manufacturing scale‑up, and regulatory milestones. The firm’s current market position is underpinned by a $1.1 billion valuation, yet its share price remains highly sensitive to clinical outcomes, partnership announcements, and broader biotech market sentiment.
Forward‑Looking Assessment
The 2.63 % intraday gain signals a short‑term rally that may be attributed to recent positive clinical data or a broader biotech sector uptick. However, the –12.99 % decline since the end of last month underscores lingering volatility and investor caution. Analysts suggest that the upcoming Q3 2026 filings—whether clinical trial updates or partnership agreements—will be pivotal in reshaping the stock’s trajectory.
Given the 200‑day moving average and the 52‑week high/low spread, technical analysis indicates that Replimune is positioned above its long‑term trend line but still within a wide volatility envelope. A disciplined approach to monitoring regulatory approvals, data readouts, and competitive dynamics will be essential for investors aiming to capitalize on the company’s growth potential.
